Plasma exosome-derived fragile site-associated tumor suppressor as a powerful prognostic predictor for patients with ovarian cancer

Authors

  • Renjing Hu Department of Laboratory Medicine, Wuxi Second People's Hospital, Jiangsu, China
  • Xiaochun Chen Department of Laboratory Medicine, Taizhou Second People's Hospital, Taizhou, Jiangsu, China
  • Shiliang Zhang Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Bin Liu Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Hao Pei Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Fan Tu Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Jun Liu Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Hao Yu Department of Interventional Oncology, Wuxi Fifth People's Hospital, Jiangsu, China

DOI:

https://doi.org/10.17305/bjbms.2021.6404

Keywords:

Fragile-site associated tumor suppressor (FATS), ovarian cancer, exosomes, prognosis, predictive value

Abstract

The objective of the study was to investigate the levels of plasma exosome-derived fragile site-associated tumor suppressor (FATS) and evaluate its prognostic predictive ability in ovarian cancer (OC) patients. Exosome-rich fractions were isolated from the plasma of 90 patients with OC enrolled in this study. The levels of plasma exosome-derived FATS were detected by ELISA. The levels of exosome-derived FATS in OC patients were significantly lower as compared to the healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were higher in OC patients with low grade (1/2), and Federation International of Gynecology and Obstetrics (FIGO) Stages I/II than those in high grade (3/4) and Stages III/IV of the disease (p = 0.003; p < 0.001), respectively. The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis or no ascites as compared to those with lymph node metastasis or ascites, respectively (both p < 0.001). The levels of plasma exosome-derived FATS were higher in OC patients having CA-125 below 35 U/ml as compared to those with CA-125 greater than 35 U/ml (p < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients with lower plasma exosome-derived FATS levels than those with higher levels (both p < 0.001). The area under the receiver operating characteristic curve of plasma exosome-derived FATS was 0.85 (95% CI: 0.76-0.91) for 5-DFS and 0.91 (95% CI: 0.83-0.96) for 5-OS prediction in patients with OC. Plasma exosome-derived FATS levels in OC patients were significantly downregulated. Low levels of plasma exosome-derived FATS had a significant relationship with FIGO Stages III/IV, high grade, ascites, higher levels of CA-125, lymph node metastasis, and prognosis of OC patients. Thus, our findings may provide insights for the development of a new strategy OC treatment.

Downloads

Download data is not yet available.
Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer

Downloads

Additional Files

Published

01-06-2022

Issue

Section

Translational and Clinical Research

Categories

How to Cite

1.
Plasma exosome-derived fragile site-associated tumor suppressor as a powerful prognostic predictor for patients with ovarian cancer. Biomol Biomed [Internet]. 2022 Jun. 1 [cited 2024 Apr. 18];22(3):453-9. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/6404

Funding data